Page 113 - Clinical Program In Primary Sclerosing Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical program in primary sclerosing cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program In Primary Sclerosing Cholangitis Today - Breaking & Trending Today

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Oakville, Ontario (Newsfile Corp. - January 21, 2021) -
Cardiol Therapeutics Inc. (
Cardiol or the
Company ), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the formation of the Data Safety Monitoring Committee ( DSMC ) and the Clinical Endpoint Committee ( CEC ) for the Company s Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States.
The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial. In order to do so, the DSMC may review unblinded study information (on a patient level or t ....

United States , Stanford University , New Brunswick , San Francisco , Jean Lucien Rouleau , Maria Rosa Costanzo , John Teerlink , Brent Mitchell , David Elsley , Trevor Burns , Kostenloser Wertpapierhandel , Courtney Bennett , George Wells , Montreal Heart Institute , University Of California , Group Heart Failure , Data Safety Monitoring Committee , Edward Hospital Center , School Of Epidemiology , Cardiol Therapeutics Inc , University Of Ottawa , Public Health , Cardiovascular Research Methods Centre , Bennett Is Mayo Quality Academy , Echocardiographic Laboratory , University Of Ottawa Heart Institute ,

numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics

numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics
numares AG and analytical instrumentation and solution provider
Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the
numares brand
AXINON
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005438/en/
numare s AI-driven, NMR-based diagnostic platform AXINON is easy to operate by laboratory technicians. (Photo: Business Wire) ....

Winton Gibbons , Volker Pfahlert , Christiane Proll , Iris Mangelschots , Group Corp , Bruker Corporation , Magnetic Group Signaling , Business Wire , Mayo Clinic , Bruker Biospin , Group Signaling , விண்டன் கிப்பன்கள் , குழு கார்ப் , ப்ரூக்கர் நிறுவனம் , காந்த குழு சமிக்ஞை , வணிக கம்பி , மயோ சிகிச்சையகம் , ப்ரூக்கர் பயோஸ்பின் , குழு சமிக்ஞை ,

Aptorum Group Limited: Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

(1)
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ( Aptorum Group or Aptorum ), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by
Staphylococcus aureus including MRSA.
Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. This milestone supports the transition of Aptorum Group to a clinical-stage company and reflects the potential of our scientific rigor and novel appr ....

Clark Cheng , Ghislaine Gasparetto , Aptorum Group Form , Aptorum Group Or , Investor Relations Department , Public Health Agency Of Canada , Actifin Financial Communications Europe , Redchip Financial Communications United States , Daptorum Group , Aptorum Group Limited Nasdaq , Aptorum International , Aptorum Group Acticule , Aptorum Group Limited , Euronext Paris , Aptorum International Limited , Public Health Agency , Health Canada , Clinical Trial Application , Chief Medical Officer , Executive Director , Group Limited , Private Securities Litigation Reform Act , French Autorit , Des March , Regulations Delegated , Relations Department ,

Teckro Looks to 2021 and Beyond: Expands Executive Team to Build on Company Mission to Humanize Clinical Trials Through Real-Time Communication

(0)
Experienced sales leader Ciaran Avitabile joins as Global Head of Sales
Clinical trials software provider Teckro announces growth of its executive team to build on 2020 s momentum that includes more than 19,800 sites globally reliant on Teckro and the expansion of its digital engagement platform to give site staff real-time communication with study experts.
Now in its 6
th year, Teckro is building on its mission to humanize the clinical trials process. For too long, research staff and monitors and sponsors have relied on outdated, manual methods of communication. The ability to engage and access critical study information in real-time eases the burden on all clinical trial stakeholders. ....

United States , Ciaran Avitabile , Teckro Youtube , Kostenloser Wertpapierhandel , Gary Hughes , Hannah Lippitt , Global Head , Veeva Systems , Teckro Digital Engagement Platform , Teckro Connect , ஒன்றுபட்டது மாநிலங்களில் , கேரி ஹக்ஸ் , உலகளாவிய தலை ,

Merck KGaA Says It Will Discontinue Bintrafusp Alfa Clinical Trial

BERLIN (dpa-AFX) - Science and technology company Merck KGaA (MKGAY.PK) announced Wednesday that the Independent Data Monitoring Committee (IDMC) recommended on Tuesday to discontinue the bintrafusp ....

Merck Kga , Data Monitoring Committee , Independent Data Monitoring Committee , மெர்க் க்க , தகவல்கள் கண்காணிப்பு குழு , சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு ,